Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07807995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrolling by invitation only Trial sites expanded: 0 → 3 locations · Start date changed from estimate of Sep 18, 2026 to Sep 17, 2026 Show 2 more changesShow less
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Sep 18, 2026 to Sep 17, 2026
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgAN).
Trial Details
NCT Number NCT07807995
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Immunoglobulin A Nephropathy
Enrollment 605 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov